These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10150468)

  • 41. [Clinical value of a new method of therapeutic control of heparin].
    Pizzuto J; Garcia S; de la Paz Reyna M; Morales MR; Avilés A; Zavala B; Ponce L; Gaos C
    Arch Inst Cardiol Mex; 1978; 48(2):373-86. PubMed ID: 666447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.
    Ten Boekel E; Böck M; Vrielink GJ; Liem R; Hendriks H; de Kieviet W
    Thromb Res; 2007; 121(3):361-7. PubMed ID: 17568658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of between-sample carryover on an automated coagulation instrument: recommendations for quality control procedures.
    Smith C; Furman A
    Clin Lab Sci; 1995; 8(5):284-7. PubMed ID: 10163338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of thrombelastography with common coagulation tests.
    Zuckerman L; Cohen E; Vagher JP; Woodward E; Caprini JA
    Thromb Haemost; 1981 Dec; 46(4):752-6. PubMed ID: 7330829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation.
    Kitchens CS
    Am J Hematol; 1988 Jan; 27(1):38-45. PubMed ID: 3128104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma.
    Yuan S; Ferrell C; Chandler WL
    Thromb Res; 2007; 120(1):29-37. PubMed ID: 16887171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-frozen transports of whole blood samples do not cause relevant bias for global coagulation tests in clinical trials evaluating the drug safety.
    Totzke U; Kuyas C
    Contemp Clin Trials; 2005 Aug; 26(4):488-502. PubMed ID: 16054581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
    Marlar RA; Bauer PJ; Endres-Brooks JL; Montgomery RR; Miller CM; Schanen MM
    Am J Clin Pathol; 1984 Oct; 82(4):436-9. PubMed ID: 6475840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Increased activated partial thrombin time: analysis of 250 cases discovered at laboratory].
    Freyburger G; Janvier G; De Cacqueray C; Dief S; Negrery H; Drouillard B
    Ann Biol Clin (Paris); 1991; 49(2):108-14. PubMed ID: 2064079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Point-of-care testing of neonatal coagulation.
    Tan K; Booth D; Newell SJ; Dear PR; Hughes C; Richards M
    Clin Lab Haematol; 2006 Apr; 28(2):117-21. PubMed ID: 16630216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of the Heptest and a chromogenic substrate method to assess anticoagulation in patients refractory to heparinization by the activated partial thromboplastin time method.
    Messmore HL; Koza M; Farid S; Wehrmacher WH
    Semin Thromb Hemost; 1994; 20(4):351-2. PubMed ID: 7899867
    [No Abstract]   [Full Text] [Related]  

  • 53. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accurate coagulation studies from heparinized radial artery catheters.
    Gregersen RA; Underhill SL; Detter JC; Schmer G; Lax K
    Heart Lung; 1987 Nov; 16(6 Pt 1):686-93. PubMed ID: 3679862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Investigation of a prolonged APTT. Different approaches taken by laboratories to achieve the same diagnosis.
    Jennings I; Kitchen DP; Kitchen S; Woods TA; Walker ID
    Int J Lab Hematol; 2013 Apr; 35(2):177-82. PubMed ID: 23113926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Experimental quality assessment of APTT-control reagent kits in the study of heparin-containing plasma in therapeutic ranges].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 Apr; (4):39-41. PubMed ID: 21735680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heparin contamination in coagulation testing and a protocol to avoid it and the risk of inappropriate FFP transfusion.
    Newman RS; Fagin AR
    Am J Clin Pathol; 1995 Oct; 104(4):447-9. PubMed ID: 7572796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy.
    Ansell J; Tiarks C; Hirsh J; McGehee W; Adler D; Weibert R
    Am J Clin Pathol; 1991 Feb; 95(2):222-7. PubMed ID: 1992612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The activated partial thromboplastin time.
    Chin JL
    N Engl J Med; 1973 Jun; 288(26):1410. PubMed ID: 4707428
    [No Abstract]   [Full Text] [Related]  

  • 60. An attempt to standardize the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration. Results of a 13 centre study.
    Reed SV; Haddon ME; Denson KW
    Thromb Res; 1994 Jun; 74(5):515-22. PubMed ID: 8085252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.